Literature DB >> 2656014

Revised immune network concepts.

H Köhler1, T Kieber-Emmons, S Srinivasan, S Kaveri, W J Morrow, S Müller, C Y Kang, S Raychaudhuri.   

Abstract

The idiotype network concept needs to be revised in order to be in agreement with current data on protein/protein interactions, with the phenomenon of T and B cell recognition of idiotopes, and with the failure of certain anti-idiotypes to stimulate a given immune response. It is proposed that the distinction among Ab2 alpha, beta, and gamma is abandoned, as well as the concept of an internal image idiotope which mimics the three-dimensional shape of nominal antigen. In place of these definitions, the concept of "network antigen" is introduced. Network antigens are potentially the entire repertoire of anti-idiotypes. However, their biological effectiveness is controlled and established by two factors: (i) the affinity to the idiotype Ig receptor; and (ii) the preexisting regulatory network segment that controls the outcome of immune stimulation or suppression. Screening for effective idiotype therapeutic agents has to be done with panels of anti-idiotype and idiotype antibodies in order to establish correlations between idiotope expression and disease progression. Recognizing the importance of network segments will be the first step in the direction toward a rational design of idiotype-based therapies.

Mesh:

Substances:

Year:  1989        PMID: 2656014     DOI: 10.1016/0090-1229(89)90197-9

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  14 in total

1.  Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus.

Authors:  E S Tackaberry; J Hamel; Y Larose; B R Brodeur
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

2.  A Cayley tree immune network model with antibody dynamics.

Authors:  R W Anderson; A U Neumann; A S Perelson
Journal:  Bull Math Biol       Date:  1993-11       Impact factor: 1.758

Review 3.  Idiotypic antibody immunotherapy of cancer.

Authors:  M B Chatterjee; K A Foon; H Köhler
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

4.  Murine monoclonal anti-idiotope antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys.

Authors:  P Chattopadhyay; J Starkey; W J Morrow; S Raychaudhuri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.

Authors:  C Y Kang; P Nara; S Chamat; V Caralli; A Chen; M L Nguyen; H Yoshiyama; W J Morrow; D D Ho; H Köhler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

6.  Assessment of safety and the immune response to the CD4 "internal antigen" mouse anti-idiotypic Mab 16D7 in four patients with SLE.

Authors:  Federico Perosa; Grazia Luccarelli; Marco Scudeletti; Maurizio Cutolo; Franco Indiveri; Franco Dammacco
Journal:  J Clin Immunol       Date:  2002-01       Impact factor: 8.317

7.  Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.

Authors:  K Irvine; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

8.  Anti-idiotype vaccines for immunity to bacterial polysaccharides: induction of functional antibodies to polysaccharide antigens of Pseudomonas aeruginosa.

Authors:  J R Schreiber
Journal:  Springer Semin Immunopathol       Date:  1993

9.  Modulation of immune response to Lol p I by pretreatment with anti-idiotypic antibody is not restricted to the idiotypic expression.

Authors:  Y Boutin; J Hébert
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

10.  The promise of the anti-idiotype concept.

Authors:  Thomas Kieber-Emmons; Bejatohlah Monzavi-Karbassi; Anastas Pashov; Somdutta Saha; Ramachandran Murali; Heinz Kohler
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.